4/25
08:08 pm
kytx
Kyverna Therapeutics Showcases miv-cel Data in SPS, gMG; CEO Eyes First Autoimmune CAR-T BLA [Yahoo! Finance]
Medium
Report
Kyverna Therapeutics Showcases miv-cel Data in SPS, gMG; CEO Eyes First Autoimmune CAR-T BLA [Yahoo! Finance]
4/23
08:12 am
kytx
Kyverna Therapeutics (KYTX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $20.00 price target on the stock.
Medium
Report
Kyverna Therapeutics (KYTX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $20.00 price target on the stock.
4/22
03:38 pm
kytx
Kyverna Therapeutics: 'Strong Buy' On Additional POC Of Miv-Cel In Myasthenia Gravis [Seeking Alpha]
Low
Report
Kyverna Therapeutics: 'Strong Buy' On Additional POC Of Miv-Cel In Myasthenia Gravis [Seeking Alpha]
4/21
06:45 pm
kytx
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
Low
Report
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
4/21
07:37 am
kytx
Kyverna Therapeutics Positive Phase 2 Readout: Deep Responses, But Very Small Sample [Seeking Alpha]
High
Report
Kyverna Therapeutics Positive Phase 2 Readout: Deep Responses, But Very Small Sample [Seeking Alpha]
4/20
08:00 am
kytx
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks
High
Report
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks
4/9
08:00 am
kytx
Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026
Medium
Report
Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026
3/26
04:02 pm
kytx
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Low
Report
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
3/21
01:31 am
kytx
Low
Report
3/13
10:38 am
kytx
Kyverna Therapeutics, Inc. (KYTX) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]
Low
Report
Kyverna Therapeutics, Inc. (KYTX) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]
3/5
04:57 pm
kytx
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026 [Yahoo! Finance]
Medium
Report
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026 [Yahoo! Finance]
3/5
04:21 pm
kytx
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026
Medium
Report
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026
3/3
08:00 am
kytx
Kyverna Therapeutics to Participate in Upcoming March Investor Conferences
Low
Report
Kyverna Therapeutics to Participate in Upcoming March Investor Conferences
2/28
01:30 am
kytx
Medium
Report
2/24
08:00 am
kytx
Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors
Low
Report
Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors
2/14
01:32 am
kytx
Kyverna Therapeutics (NASDAQ:KYTX) was downgraded by analysts at
Wall St
Medium
Report
Kyverna Therapeutics (NASDAQ:KYTX) was downgraded by analysts at
Wall St
2/3
08:00 am
kytx
Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer
Low
Report
Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer